OSWALSEEDSOther Agricultural Products
Shreeoswal Seeds and Chemicals Ltd — Profit & Loss Statement
₹10.43
-1.67%
Shreeoswal Seeds and Chemicals Ltd Profit & Loss Statement (Annual)
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | -0.01 Cr | -0.05 Cr | -0.05 Cr | -0.05 Cr |
| Tax Rate For Calcs | 0.23 | 0.28 | 0.28 | 0.28 |
| Normalized EBITDA | 0.85 Cr | 12.10 Cr | 10.60 Cr | 7.93 Cr |
| Total Unusual Items | -0.04 Cr | -0.18 Cr | -0.18 Cr | -0.19 Cr |
| Total Unusual Items Excluding Goodwill | -0.04 Cr | -0.18 Cr | -0.18 Cr | -0.19 Cr |
| Net Income From Continuing Operation Net Minority Interest | -4.16 Cr | 5.71 Cr | 5.44 Cr | 3.65 Cr |
| Reconciled Depreciation | 0.52 Cr | 0.43 Cr | 0.39 Cr | 0.30 Cr |
| Reconciled Cost Of Revenue | 262.87 Cr | 254.85 Cr | 226.10 Cr | 150.21 Cr |
| EBIT | 0.29 Cr | 11.49 Cr | 10.03 Cr | 7.44 Cr |
| Net Interest Income | -5.91 Cr | -3.63 Cr | -2.57 Cr | -2.43 Cr |
| Interest Expense | 5.67 Cr | 3.59 Cr | 2.46 Cr | 2.38 Cr |
| Interest Income | 0.06 Cr | 0.07 Cr | 0.05 Cr | 35000.00 |
| Normalized Income | -4.13 Cr | 5.84 Cr | 5.56 Cr | 3.79 Cr |
| Net Income From Continuing And Discontinued Operation | -4.16 Cr | 5.71 Cr | 5.44 Cr | 3.65 Cr |
| Total Expenses | 268.49 Cr | 260.66 Cr | 230.25 Cr | 153.66 Cr |
| Rent Expense Supplemental | 0.01 Cr | 90000.00 | 0.00 | 8000.00 |
| Diluted Average Shares | 9.15 Cr | 9.15 Cr | 9.15 Cr | 9.15 Cr |
| Basic Average Shares | 9.15 Cr | 9.15 Cr | 9.15 Cr | 9.15 Cr |
| Diluted EPS | -0.45 | 0.62 | 0.59 | 0.40 |
| Basic EPS | -0.45 | 0.62 | 0.59 | 0.40 |
| Diluted NI Availto Com Stockholders | -4.16 Cr | 5.71 Cr | 5.44 Cr | 3.65 Cr |
| Net Income Common Stockholders | -4.16 Cr | 5.71 Cr | 5.44 Cr | 3.65 Cr |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -4.16 Cr | 5.71 Cr | 5.44 Cr | 3.65 Cr |
| Net Income Including Noncontrolling Interests | -4.16 Cr | 5.71 Cr | 5.44 Cr | 3.65 Cr |
| Net Income Discontinuous Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Continuous Operations | -4.16 Cr | 5.71 Cr | 5.44 Cr | 3.65 Cr |
| Tax Provision | -1.22 Cr | 2.19 Cr | 2.14 Cr | 1.41 Cr |
| Pretax Income | -5.38 Cr | 7.90 Cr | 7.57 Cr | 5.06 Cr |
| Other Non Operating Income Expenses | 0.04 Cr | 0.04 Cr | 0.05 Cr | 0.09 Cr |
| Selling And Marketing Expense | 0.76 Cr | 0.60 Cr | 0.50 Cr | 0.43 Cr |
| General And Administrative Expense | 0.37 Cr | 0.26 Cr | 0.12 Cr | 0.22 Cr |
| Rent And Landing Fees | 79000.00 | 90000.00 | 0.00 | 8000.00 |
| Gross Profit | 6.16 Cr | 17.48 Cr | 14.42 Cr | 11.01 Cr |
| Cost Of Revenue | 262.87 Cr | 254.85 Cr | 226.10 Cr | 150.21 Cr |
| Total Revenue | 269.03 Cr | 272.33 Cr | 240.52 Cr | 161.22 Cr |
| Operating Revenue | 269.03 Cr | 272.33 Cr | 240.52 Cr | 161.22 Cr |
| EBITDA | 0.81 Cr | 11.92 Cr | 10.42 Cr | 7.74 Cr |
| Special Income Charges | -0.05 Cr | -0.18 Cr | -0.18 Cr | -0.19 Cr |
| Write Off | 0.05 Cr | 0.18 Cr | 0.18 Cr | 0.19 Cr |
| Net Non Operating Interest Income Expense | -5.91 Cr | -3.63 Cr | -2.57 Cr | -2.43 Cr |
| Total Other Finance Cost | 0.31 Cr | 0.11 Cr | 0.16 Cr | 0.05 Cr |
| Interest Expense Non Operating | 5.67 Cr | 3.59 Cr | 2.46 Cr | 2.38 Cr |
| Interest Income Non Operating | 0.06 Cr | 0.07 Cr | 0.05 Cr | 35000.00 |
| Operating Income | 0.54 Cr | 11.67 Cr | 10.27 Cr | 7.56 Cr |
| Operating Expense | 5.62 Cr | 5.81 Cr | 4.15 Cr | 3.45 Cr |
| Other Operating Expenses | 0.69 Cr | 1.02 Cr | 0.50 Cr | 0.44 Cr |
| Depreciation And Amortization In Income Statement | 0.52 Cr | 0.43 Cr | 0.39 Cr | 0.30 Cr |
| Depreciation Income Statement | 0.52 Cr | 0.43 Cr | 0.39 Cr | 0.30 Cr |
| Research And Development | 0.31 Cr | 0.21 Cr | 0.16 Cr | 0.12 Cr |
| Selling General And Administration | 1.13 Cr | 0.86 Cr | 0.62 Cr | 0.65 Cr |
| Other Special Charges | — | 6000.00 | — | — |
| Minority Interests | — | — | 0.00 | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Shreeoswal Seeds and Chemicals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.